Steering Complexities Of Oral Solid Formulation Development And Leveraging CDMO Partnership

The oral solid dose formulation market is a significant segment in the pharmaceutical industry, accounting for about 60% of all dosage forms. However, drug developers are constantly challenged to create innovative formulations that address solubility and bioavailability issues, drug stability concerns, and improve patient experience.

One of the key challenges in oral solid dose development is low water solubility, which can lead to low bioavailability. To overcome this, specialized technologies and excipients are required. Polymeric carriers and excipient advancements play a crucial role in ensuring API stability and extending shelf-life.

In order to navigate the complexities of oral solid dose development and adhere to regulatory frameworks, many emerging pharma companies are turning to contract development and manufacturing organizations (CDMOs) for assistance. CDMOs have the expertise and state-of-the-art facilities to handle formulation development and manufacturing, while following industry standards and ensuring trust.

Choosing the right CDMO partner is crucial for meeting expectations, quality standards, timelines, and budgets. Finding a CDMO with accessible and transparent teams enables open communication with project managers and pharmaceutical scientists. Collaborating with an experienced CDMO can provide the expertise and facilities needed to navigate these oral solid dose formulation complexities and ensure compliance with regulatory frameworks.